Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...

Advances in AI, genomics, and liquid biopsy are reshaping cancer care, but systemic gaps persist in access and funding, ...

The partnership's initial focus will be on preclinical evaluation of TLS’s boron-10 drugs in cellular and animal models.

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

Engine Biosciences (Engine), a company pioneering cancer medicines informed by its proprietary machine learning and ...

Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work ...

Survey results revealed a widespread - and often misguided - belief that subcutaneous delivery volumes must be limited to 3 ...

Champions Oncology, Inc.’s CSBR share price has surged by 8.58%, which has investors questioning if this is right time to ...